Kyverna Therapeutics KYTX 深 滬
等待開盤 09-06 09:30:00 美东时间
3.94
+0.310
+8.54%
華盛通- 最 高3.94
- 今 開3.68
- 成交量 21.69万股
- 最 低 3.60
- 昨 收 3.63
- 總市值 1.70亿
- 52周最高 7.35
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.78
- 委 比 -99.84%
- 總股本 4321.89万
- 歷史最高 35.06
- 量 比 0.94
- 振 幅 9.37%
- 歷史最低 1.78
- 每 手 1
- 風險率 8.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
Kyverna Therapeutics announces Phase 3 trial design for its CAR T therapy KYV-101 targeting myasthenia gravis (MG) and stiff person syndrome (SPS). The trial, aligned with FDA guidelines, aims to demonstrate KYV-101's superiority over standard-of-care treatments. Key endpoints include changes in MG-ADL and QMG scores. KYV-101 has shown potential for durable remission and could be the first FDA-approved therapy for SPS. The Company will host a vir...
08-28 12:00
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
Kyverna Therapeutics' CEO Warner Biddle will participate in three fireside chat sessions at the 2025 Wells Fargo Healthcare Conference (Sept 3), Morgan Stanley 23rd Annual Global Healthcare Conference (Sept 8), and H.C. Wainwright 27th Annual Global Investment Conference (Sept 9). Kyverna, a biopharmaceutical company focused on cell therapies for autoimmune diseases, is advancing its lead CAR T-cell therapy KYV-101 for stiff person syndrome, myas...
08-25 20:02
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in autoimmune disease.
08-21 03:29
William Blair Initiates Coverage On Kyverna Therapeutics with Outperform Rating
William Blair analyst Sami Corwin initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Outperform rating.
08-20 21:01
Kyverna Therapeutics Q2 EPS $(0.97) Beats $(1.04) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.04) by 7.09 percent. This is a 44.78 percent decrease over losses of $(0.67) per share
08-13 04:21
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. Most recently, Grasso served as CFO of Alector, a clinical...
06-30 21:32
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
HC Wainwright & Co. Upgrades Kyverna Therapeutics to Buy, Raises Price Target to $5
HC Wainwright & Co. analyst Mitchell Kapoor upgrades Kyverna Therapeutics (NASDAQ:KYTX) from Neutral to Buy and raises the price target from $4 to $5.
05-27 18:56
快讯 | Kyverna Therapeutics Inc - 预计将在2026年上半年提交Kyv-101的BLA申请
Kyverna Therapeutics Inc - Anticipates Bla Filing for Kyv-101 in 1H 2026
05-14 04:26
Kyverna Therapeutics Q1 EPS $(1.03) Misses $(0.99) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(0.99) by 4.04 percent. This is a 8.04 percent increase over losses of $(1.12) per share
05-14 04:14
